NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
On the primary endpoint at 28 days, PF-03187207 showed a 12% improvement over Xalatan® 0.005% which did not reach statistical significance. However, a statistically significant advantage over Xalatan® 0.005% was observed on a number of secondary endpoints (p<0.05).
Pfizer has taken the decision not to launch a global phase 3 development program for PF-03187207. Nevertheless, Pfizer has reaffirmed its commitment to the ongoing joint research program with NicOx, which aims to identify the most active nitric oxide-donating prostaglandin analogs for development on a global basis.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.